The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of "DTX-021"—a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the South America neurotoxin market to grow.
The South America neurotoxin market is segmented into Brazil, Argentina, Venezuela, and the Rest of South America. Growth in this market is mainly driven by the growing adoption of minimally invasive and non-invasive aesthetic procedures, rising adoption among geriatric individuals, increasing public awareness about cosmetic procedures, availability of technologically advanced & user-friendly products, and increasing demand for aesthetic treatments. The regional market is likely to propel during the forecasted period owing to the recent technological developments that have made a direct impact on the economy of Brazil that has advanced to a large extent. In Brazil, the adoption of minimally invasive and non-invasive cosmetic procedures with a broad range of indications, such as botulinum-toxin-based treatment, are the major market drivers. The brand names of botulinum toxin A formulations available in Brazil involve Botox, Xeomin, Dysport, Botulift, and Prosigne. Additionally, the International Society of Aesthetics and Plastic Surgeons (ISAPS) 2018 report reveals that botulinum toxin-based treatment was the most common non-surgical procedure performed in Brazil, accounting for 51% (approx. 392,530) of the total non-surgical procedures. The cost savings advantage and higher work efficiencies achieved are cited as the major attracting points for manufacturing companies to establish bases in South America.
South America Neurotoxins Market Segmentation
The South America neurotoxins market is segmented into product type, application, end user, and country.
Based on product type, the South America neurotoxins market is subsegmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.
Based on application, the South America neurotoxins market is segmented into therapeutic and aesthetic. The aesthetic segment held a larger market share in 2023.
Based on end user, the South America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the South America neurotoxins market is segmented into Brazil, Argentina, Venezuela, and the Rest of South America. Brazil dominated the market share in 2023.
AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA are among the leading companies operating in the South America neurotoxins market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 280.48 Million |
| Market Size by 2028 | US$ 525.57 Million |
| CAGR (2023 - 2028) | 13.4% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
The South America Neurotoxins Market is valued at US$ 280.48 Million in 2023, it is projected to reach US$ 525.57 Million by 2028.
As per our report South America Neurotoxins Market, the market size is valued at US$ 280.48 Million in 2023, projecting it to reach US$ 525.57 Million by 2028. This translates to a CAGR of approximately 13.4% during the forecast period.
The South America Neurotoxins Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America Neurotoxins Market report:
The South America Neurotoxins Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America Neurotoxins Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America Neurotoxins Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For South America Neurotoxins Market
